• 1.

    DCCT/EDIC Research Group: Effect of intensive diabetes treatment on albuminuria in type 1 diabetes: Long-term follow-up of the Diabetes Control and Complications Trial and Epidemiology of Diabetes Interventions and Complications study. Lancet Diabetes Endocrinol 2014; 2:793800.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 2.

    Zoungas S, et al.. Follow-up of blood-pressure lowering and glucose control in type 2 diabetes. N Engl J Med 2014; 371:13921406.

  • 3.

    Perkovic V, et al.. Intensive glucose control improves kidney outcomes in patients with type 2 diabetes. Kidney Int 2013; 83:517523.

  • 4.

    Lewis EJ, et al.. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 1993; 329:14561462.

  • 5.

    Fried LF, et al.. Combined angiotensin inhibition for the treatment of diabetic nephropathy. N Engl J Med 2013; 369:18921903.

  • 6.

    Perkovic V, et al.. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med 2019; 380:22952306.

  • 1.

    Chan GC and Tang SC. Diabetic nephropathy: Landmark clinical trials and tribulations. Nephrol Dial Transplant 2016; 31:359368.

  • 2.

    Diabetes Control and Complications Trial Research Group, et al.. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329:977986.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 3.

    DCCT/EDIC Research Group. Effect of intensive diabetes treatment on albuminuria in type 1 diabetes: Long-term follow-up of the Diabetes Control and Complications Trial and Epidemiology of Diabetes Interventions and Complications study. Lancet Diabetes Endocrinol 2014; 2:793800.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 4.

    Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998; 352:837853.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 5.

    Perkovic V, et al.. Intensive glucose control improves kidney outcomes in patients with type 2 diabetes. Kidney Int 2013; 83:517523.

  • 6.

    Action to Control Cardiovascular Risk in Diabetes Study, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008; 358:25452559.

  • 7.

    Lewis EJ, et al.. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 1993; 329:14561462.

  • 8.

    Brenner BM, et al.. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345:861869.

  • 9.

    Lewis EJ, et al.. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345:851860.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 10.

    Haller H, et al.. Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes. N Engl J Med 2011; 364:907917.

  • 11.

    Mann JF, et al.. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): A multicentre, randomised, double-blind, controlled trial. Lancet 2008; 372:547553.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 12.

    Fried LF, et al.. Combined angiotensin inhibition for the treatment of diabetic nephropathy. N Engl J Med 2013; 369:18921903.

  • 13.

    Parving HH, et al.. Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med 2012; 367:22042213.

  • 14.

    de Zeeuw D, et al.. Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease. N Engl J Med 2013; 369:24922503.

  • 15.

    Mann JF, et al.. Avosentan for overt diabetic nephropathy. J Am Soc Nephrol 2010; 21:527535.

  • 16.

    Perkovic V, et al.. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med 2019; 380:22952306.

Clinical Trials on Diabetic Kidney Disease: What Have We Learned from Landmark Trials?

Vecihi Batuman Vecihi Batuman is with the department of internal medicine and chief, division of nephrology, at Tulane University.

Search for other papers by Vecihi Batuman in
Current site
Google Scholar
PubMed
Close
Restricted access
Save